Medical Radiology and Radiation Safety, 2016, Vol. 61. No. 5. P. 27-41


A.N. Koterov, L.N. Ushenkova, A.P. Biryukov, A.S. Samoilov


A.I. Burnasyan Federal Medical Biophysical Center of FMBA, Moscow, Russia, e-mail: Этот адрес электронной почты защищен от спам-ботов. У вас должен быть включен JavaScript для просмотра.


Results of pooled-analysis of primary data in the database formed from molecular epidemiological sources on RET/PTC gene rearrangements frequency in papillary thyroid carcinoma developed spontaneously and after Chernobyl nuclear power plant accident showed declined chronological trends for RET/PTC1, RET/PTC3 and RET/PTC after the incident separately for cohorts from Europe, USA + Canada and the Asia-Pacific region have been demonstrated. The above trend for RET/PTC3 and RET/PTC in total was similar to trends observed in carcinomas of Chernobyl etiology (Belarus, Russia and Ukraine), although there was no apparent time dependence for RET/PTC1 level in this case. Observed trends could not be connected to any chronological changes in the degree of carcinoma differentiation or age factor for tumor. As chronological changes of RET/PTC frequency in carcinomas in different continents and regions can not be explained by the radiation factor of the Chernobyl accident, it was concluded about the predominant contribution of the ‘human factor’ associated with ‘overestimation’ and ‘overdiagnosis’ of early forms of thyroid tumors in connection with increased vigilance after the Chernobyl accident. Apparently, these factors, along with improvement of instrumental methods at that time, coupled with the ‘aggressive surgery’, took place worldwide resulting in detection of early forms of the occult carcinomas and microcarcinomas. The frequency of RET/PTC in such tumors is higher than in conventional tumors. The frequence of these subjective factors is likely to decrease with time from the date of the Chernobyl accident.

Key words: pooled-analysis, RET/PTC gene rearrangements, papillary thyroid carcinoma, the time after the Chernobyl accident, overestimation


  1. Prisyazhiuk A., Pjatak O.A., Buzanov V.A. et al. Cancer in the Ukraine, post-Chernobyl. Lancet. 1991. Vol. 338. No. 8778. P. 1334-1335.
  2. UNSCEAR Report to the General Assembly, with Scientific Annex. Annex J. Exposures and effects of the Chernobyl accident. New York. 2000. P. 451-566.
  3. Parshkov M. Analysis of thyroid cancer morbidity. In: Lushnikov E.F., Tsyb A.F., Yamashita S. Thyroid cancer in Russia after Chernobyl. Moscow, Meditsina, 2006. P. 36-59. (Russian with English summary).
  4. Ron E., Lubin J.H., Shore R.E. et al. Thyroid cancer after exposure to external radiation: a pooled analysis of seven studies. Radiat. Res. 1995. Vol. 141. No. 3. P. 259-277.
  5. UNSCEAR Report to the General Assembly, with Scientific Annex. Annex D. Health effects due to radiation from the Chernobyl accident. United Nations. New York. 2011. P. 47-219.
  6. NAS/NRC, Health Risks from Exposure to Low Levels of Ionizing Radiation: BEIR VII Phase 2. Board on Radiation Effects Research. National Research Council of the National Academies. Washington. D.C.
  7. ICRP Publication Low-dose Extrapolation of Radiation-related Cancer Risk. Ann. ICRP. Ed. by J. Valentin. Amsterdam, New York: Elsevier. 2006. 147 p.
  8. UNSCEAR Report to the General Assembly, with Scientific Annex. Annex B. Uncertainties in risk estimates for radiation-induced cancer. New York. 2014. 219 p.
  9. Steliarova-Foucher, Stiller C.A., Pukkala E. et al. Thyroid cancer incidence and survival among European children and adolescents (1978-1997): report from the Automated Childhood Cancer Information System project. Eur. J. Cancer. 2006. Vol. 42. No. 13. P. 2150-2169.
  10. Guskova K., Galstian I.A., Gusev I.A. Chernobyl nuclear power plant accident (1986-2011): Implications for health, reflections doctor. Ed. by of member-correspondent. RAMS A.K. Gus’kova. Moscow: Ed. by State Scientific Research Center n.a. A.I. Burnasyan Medical Biophysical Center of Federal Medical Biological Agency. 2011. 254 p. (Russian).
  11. ShirahigeY., Ito , Ashizawa al. Childhood thyroid cancer: comparison of Japan and Belarus. Endocrinol. J. 1998. Vol. 45. No. 2. P. 203-209.
  12. UNSCEAR 2000. Report to the General Assembly, with Scientific Annex I. Epidemiological evaluation of radiation-induced cancer. United Nations. New York. 2000. P. 297-450.
  13. Likhtarev I., Minenko V., Khrouch V., Bouville A. Uncertainties in thyroid dose reconstruction after Chernobyl. Radiat. Prot. Dosimetry. 2003. Vol. 105. No. 1-4. P. 601-608.
  14. Gavrilin Y., Khrouch V., Shinkarev et al. Individual thyroid dose estimation for a case-control study of Chernobyl-related thyroid cancer among children of Belarus-part I: 131I, short-lived radioiodines (132I, 133I, 135I), and short-lived radiotelluriums (131mTe and 132Te). Health Phys. 2004. Vol. 86. No. 6. P. 565-585.
  15. Drozdovitch V., Khrouch V., Maceika et al. Reconstruction of radiation doses in a case-control study of thyroid cancer following the Chernobyl accident. Health Phys. 2010. Vol. 99. No. 1. P. 1-16.
  16. UNSCEAR 2006. Report to the General Assembly, with Scientific Annexes. Annex A. Epidemiological studies of radiation and cancer. United New York. 2008. P. 17-322.
  17. Lushnikov F., Vtyurin B.M., Tsyb A.F. Thyroid microcarcinoma. Moscow, Medicine. 2003. 261 p. (Russian).
  18. Jargin V. On the RET rearrangements in Chernobyl-related thyroid cancer. J. Thyroid Res. 2012. Vol. 2012. Article ID 373879.
  19. Verkooijen M., Fioretta G., Pache J.-C. et al. Diagnostic changes as a reason for the increase in papillary thyroid cancer incidence in Geneva, Switzerland. Cancer Causes and Control. 2003. Vol. 14. No. 1. P. 13-17.
  20. Chen A.Y., Jemal A., Ward M. Increasing incidence of differentiated thyroid cancer in the United States, 1988- 2005. Cancer. 2009. Vol. 115. No. 16. P. 3801-3807.
  21. Jacob P., Bogdanova T.I., Buglova et al. Thyroid cancer among Ukrainians and Belarussians who were children or adolescents at the time of the Chernobyl accident. J. Radiol. Prot. 2006. Vol. 26. No. 1. P. 51-67.
  22. Rozhko V., Masyakin V.B., Madyrov E.A., Okeanov A.E. Screening effect role in estimation of thyroid pathology cohort study results. Medical Radiology and Radiation Safety. 2010. Vol. 55. No.1. P. 19-23. (Russian with English summary. Available from:
  23. Jargin V. Thyroid cancer after Chernobyl: mechanisms of overestimation. Radiat. Environ. Biophys. 2011. Vol. 50. No. 4. P. 603-604.
  24. Ron E., Lubin J., Schneider A.B. Thyroid cancer incidence. Nature. 1992. Vol. 360. No. 6400. P. 113.
  25. Schneider B., Ron E., Lubin J. et al. Dose-response relationships for radiation-induced thyroid cancer and thyroid nodules: evidence for the prolonged effects of radiation on the thyroid. J.Clin. Endocrinol. Metab. 1993. Vol. 77. No. 2. P. 362-369.
  26. Rozhko V., Masyakin V.B., Madyrov E.A., Okeanov A.E. Screening effect role in estimation of thyroid pathology cohort study results. Medical Radiology and Radiation Safety. 2010. Vol. 55. No.1. P. 19-23. (Russian with English summary. Available from:
  27. Kaiser C., Jacob P., Blettner M., Vavilov S. Screening effects in risk studies of thyroid cancer after the Chernobyl accident. Radiat. Environ. Biophys. 2009. Vol. 48. No. 2. P. 169-179.
  28. Morris L.G., Sikora A.G., Tosteson T., Davies L. The increasing incidence of thyroid cancer: the influence of access to care. Thyroid. 2013. Vol. 23. No. 7. P. 885-891.
  29. Cardis E., Hatch M. The Chernobyl accident - an epidemiological perspective. Clin. Oncol. (R.Coll. Radiol.). 2011. Vol. 23. No. 4. P. 251-260.
  30. Belfiore A., Russo D., Vigneri R., Filetti S. Graves’ disease, thyroid nodules and thyroid cancer. Clinical Endocrinology. 2001. Vol. 55. No. 6. P. 711-718.
  31. Malenchenko F., Vasilenko I.Ya., Vasilenko O.I. Iodine metabolism and pathologic process in the thyroid gland under radioiodine lesions in the regions of goitrous endemia. Radiation biology. Radioecology. 2007. Vol. 47. No. 4. P. 435-443. (Russian with English summary. PubMed).
  32. Shakhtarin V.V., Tsyb F., Stepanenko V.F. et al. Iodine deficiency, radiation dose, and the risk of thyroid cancer among children and adolescents in the Bryansk region of Russia following the Chernobyl power station accident. Int. J. Epidemiol. 2003. Vol. 32. No. 4. P. 584-591.
  33. Bolshova V., Tronko N.D., Van Middlesworth L. Iodine deficiency in Ukraine. Acta Endocrinol. (Copenh). 1993. Vol. 129. No. 6. P. 594.
  34. UNSCEAR 2013. Report to the General Assembly, with Scientific Vol. II. Annex B. Effects of radiation exposure of children. New York. 2013. P. 1-268.
  35. Jacob P., Kenigsberg Y., Zvonova I. et al. Childhood exposure due to the Chernobyl accident and thyroid cancer risk in contaminated areas of Belarus and Russia. J. Cancer. 1999. Vol. 80. No.9. P. 1461-1469.
  36. Thompson E., Mabuchi K., Ron E. et al. Cancer incidence in atomic bomb survivors. Part II: Solid tumors, 1958-1987. Radiat. Res. 1994. Vol. 137. No. 2. Suppl. P. S17-S67.
  37. Preston L., Ron E., Tokuoka S. et al. Solid cancer incidence in atomic bomb survivors: 1958-1998. Radiat Res. 2007. Vol. 168. No. 1. P. 1-64.
  38. Furukawa K., Preston D., Funamoto S. et al. Long-term trend of thyroid cancer risk among Japanese atomic-bomb survivors: 60 years after exposure. J. Cancer. 2013. Vol. 132. No. 5. P. 1222-1226.
  39. Takahashi M., Ritz J., Cooper G.M. Activation of a novel human transforming gene, ret, by DNA rearrangement. Cell. 1985. Vol. 42. No. 2. P. 581-588.
  40. Fusco A., Santoro M. 20 years of RET/PTC in thyroid cancer: clinico-pathological correlations. Arq. Bras. Endocrinol. Metabol. 2007. Vol. 51. No. 5. P. 731-735.
  41. Nikiforov Y.E., Nikiforova N. Molecular genetics and diagnosis of thyroid cancer. Nat. Rev. Endocrinol. 2011. V.7. No. 10. P. 569-580.
  42. Romei C., Elisei R. RET/PTC translocations and clinico-pathological features in human papillary thyroid carcinoma. Front. Endocrinol. 2012. Vol. 3. Article 54.
  43. Schoetz U., Saenko V., Yamashita S., Thomas G.A. Molecular biology studies of Ukrainian thyroid cancer after Chernobyl. In: Thyroid cancer in Ukraine after Chernobyl. Dosimetry, epidemiology, pathology, molecular biology. Ed. by T. Bogdanova, V. Saenko, G.A. Thomas, Likhtarov, S. Yamashita. 2014. Nagasaki Association for Hibakushas’ Medical Care (NASHIM). Nagasaki: IN-TEX. 2014. P. 143-174.
  44. Ushenkova N., Koterov A.N., Biryukov A.P. RET/PTC gene rearrangements in the sporadic and radiogenic thyroid tumors: molecular genetics, radiobiology and molecular epidemiology. Radiat. Biology. Radioecology (Moscow). 2015. Vol. 55. No. 3. P. 229-249. (Russian with English summary. PubMed).
  45. Rabes M., Demidchik E.P., Sidorow J.D. et al. Pattern of radiation-induced RET and NTRK1 rearrangements in 191 post-chernobyl papillary thyroid carcinomas: biological, phenotypic, and clinical implications. Clin. Cancer Res. 2000. Vol. 6. No. 3. P. 1093-1103.
  46. Rabes H.M. Gene rearrangements in radiation-induced thyroid. Med. Pediatr. Oncol. 2001. Vol. 36. No. 5. P. 574-582.
  47. Tuttle M., Lukes Y., Onstad L. et al. RET/PTC activation is not associated with individual radiation dose estimates in a pilot study of neoplastic thyroid nodules arising in Russian children and adults exposed to Chernobyl fallout. Thyroid. 2008. Vol. 18. No. 8. P. 839-846.
  48. Pisarchik V., Ermak G., Demidchik E.P. et al. Low prevalence of the ret/PTC3r1 rearrangement in a series of papillary thyroid carcinomas presenting in Belarus ten years post-Chernobyl. Thyroid. 1998. Vol. 8. No. 11. P. 1003-1008.
  49. Smida J., Salassidis K., Hieber L. et al. Distinct frequency of ret rearrangements in papillary thyroid carcinomas of children and adults from Belarus. Int. J. Cancer. 1999. Vol. 80. No. 1. P. 32-38.
  50. Williams Twenty years’ experience with post-Chernobyl thyroid cancer. Best Pract. Res. Clin. Endocrinol. Metab. 2008. Vol. 22. No. 6. P. 1061-1073.
  51. Menicali E., Moretti S., Voce P. et al. Intracellular signal transduction and modification of the tumor microenvironment induced by RET/PTCs in papillary thyroid carcinoma. Front. Endocrinol (Lausanne). 2012. Vol. 3. Article 67.
  52. Hamatani K., Eguchi H., Ito R. et al. RET/PTC Rearrangements preferentially occurred in papillary thyroid cancer among atomic bomb survivors exposed to high radiation dose. Cancer Res. 2008. Vol. 68. No. 17. P. 7176-7182.
  53. Nakachi K., Hayashi T., Hamatani K. et al. Sixty years of follow-up of Hiroshima and Nagasaki survivors: current progress in molecular epidemiology studies. Mutat. Res. 2008. Vol. 659. No. 1-2. P. 109-117.
  54. Romei C., Fugazzola L., Puxeddu E. et al. Modifications in the papillary thyroid cancer gene profile over the last 15 years. J. Clin. Endocrinol. Metab. 2012. Vol. 97. No. 9. P. E1758-E1765.
  55. Agate L., Lorusso L., Elisei R. New and old knowledge on differentiated thyroid cancer epidemiology and risk factors. J. Endocrinol. Invest. 2012. Vol. 35. No. 6. P. 3-9.
  56. Jung K., Little M.P., Lubin J.H. et al. The increase in thyroid cancer incidence during the last four decades is accompanied by a high frequency of BRAF mutations and a sharp increase in RAS mutations. J. Clin. Endocrinol. Metab. 2014. Vol. 99. No. 2. P. E276-E285.
  57. UNSCEAR Report to the General Assembly, with Scientific Annex. Annexes C, D. Exposures from Chernobyl accident. United Nations. New York, 1988. P. 3-74; 309-374.
  58. UNSCEAR 2008. Report to the General Assembly, with Scientific Annex. Volume I. Annex A. Medical radiation exposures. United Nations. New York, 2010. P. 23-220.
  59. Viglietto G., Chiappetta G., Marchinez-Tello F.J. et al. RET/PTC oncogene activation is an early event in thyroid carcinogenesis. Oncogene. 1995. Vol. No. 11. P. 1207-1210.
  60. Tallini G., Santoro M., Helie M. et al. RET/PTC oncogene activation defines a subset of papillary thyroid carcinomas lacking evidence of progression to poorly differentiated or undifferentiated tumor phenotypes. Clin. Cancer Res. 1998. Vol. 4. No. 2. P. 287-294.
  61. Sugg L., Ezzat Sh., Rosen I.B. et al. Distinct multiple RET/PTC gene rearrangements in multifocal papillary thyroid neoplasia. J. Clin. Endocrinol. Metab. 1998. Vol. 83. No. 11. P. 4116-4122.
  62. Corvi R., Martinez-Alfaro M., Harach H.R. et al. Frequent RET rearrangements in thyroid papillary microcarcinoma detected by interphase fluorescence in situ hybridization. Lab. Invest. 2001. Vol. 81. No. 12. P. 1639-1645.
  63. Ushenkova N., Koterov A.N., Biryukov A.P. Pooled analysis of RET/PTC gene rearrangement rate in sporadic and radiogenic thyroid papillary carcinoma. Radiat. Biology. Radioecology (Moscow). 2015. Vol. 55. No. 4. P. 355-388. (Russian with English summary. PubMed).
  64. Koterov N., Ushenkova L.N., Biryukov A.P. Gene markers of radiogenic thyroid cancer: relevance of search and present state of problem. Radiation biology. Radioecology (Moscow). 2015. Vol. 55. No. 2. P. 117-135. (Russian with English summary. PubMed).
  65. Friedenreich M. Methods for pooled analyses of epidemiologic studies. Epidemiology. 1993. Vol.4. No. 4. P. 295-302.
  66. Blettner M., Sauerbrei W., Schlehofer B. et al. Traditional reviews, meta-analyses and pooled analyses in epidemiology. Int. J. Epidemiol. 1999. Vol. 28. No. 1. P. 1-9.
  67. Friedenreich M. Commentary: Improving pooled analyses in epidemiology. Int. J. Epidemiol. 2002. Vol. 31. No. 1. P. 86-87.
  68. Bravata M., Olkin I. Simple pooling versus combining in meta-analysis. Eval. Health Prof. 2001. Vol. 24. No. 2. P. 218-230.
  69. Bonassi S., Norppa H., Ceppi M. et al. Chromosomal aberration frequency in lymphocytes predicts the risk of cancer: results from a pooled cohort study of 22358 subjects in 11 countries. Carcinogenesis. 2008. Vol. 29. No. 6. P. 1178-1183.
  70. Higgins P., Thompson S.G., Deeks J.J., Altman D.G. Measuring inconsistency in meta-analyses. Brit. Med. J. 2003. Vol. 327. No. 7414. P. 557-560.
  71. Di Cristofaro , Vasko V., Savchenko V. RET/PTC1 and RET/PTC3 in thyroid tumors from Chernobyl liquidators: comparison with sporadic tumors from Ukrainian and French patients. Endocr. Relat. Cancer. 2005. Vol. 12. No. 1. P. 173-183.
  72. Davidescu D., Iacob O. Thyroid cancer incidence after Chernobyl accident in Eastern Romania. International Journal of Radiation Medicine (Kiev). 2004. Vol. 6. No. 1-4. P. 30-37.
  73. Cardis E., Krewski , Boniol M. et al. Estimates of the cancer burden in Europe from radioactive fallout from the Chernobyl accident. Int. J. Cancer. 2006. Vol. 119. No. 6. P. 1224-1235.
  74. Ameziane-El-Hassani, Boufraqech M., Lagente-Chevallier O. et al. Role of H2O2 in RET/PTC1 chromosomal rearrangement produced by ionizing radiation in human thyroid cells. Cancer Res. 2010. Vol. 70. No. 10. P. 4123-4132.
  75. Gandhi M., Dillon L.W., Pramanik S. et al. DNA breaks at fragile sites generate oncogenic RET/PTC rearrangements in human thyroid cells. Oncogene. 2010. Vol. 29. No. 15. P. 2272-2280.
  76. Evdokimova V., Gandhi , Rayapureddi J. et al. Formation of carcinogenic chromosomal rearrangements in human thyroid cells after induction of double-strand DNA breaks by restriction endonucleases. Endocr. Relat. Cancer. 2012. Vol. 19. No. 3. P. 271-281.
  77. Chen Y., Jemal A., Ward E.M. Increasing incidence of differentiated thyroid cancer in the United States, 1988- 2005. Cancer. 2009. Vol. 115. No. 16. P. 3801-3807.
  78. Blomberg M., Feldt-Rasmussen U., Andersen K.K., Kjaer S.K. Thyroid cancer in Denmark 1943-2008, before and after iodine supplementation. Int. J. Cancer 2012. Vol. 131. No. 10. P. 2360-2366.
  79. Santoro M., Carlomagno F., Hay I.D. et al. RET oncogene activation in human thyroid neoplasms is restricted to the papillary cancer subtype. J. Clin. Invest. 1992. Vol. 89. No. 5. P. 1517-1522.
  80. Mayr B., Brabant G., Goretzki P. et al. RET/PTC-1, -2, and -3 oncogene rearrangements in human thyroid carcinomas: implications for metastatic potential?. J. Clin. Endocrinol. Metab. 1997. Vol. 82. No. 4. P. 1306-1367.
  81. Soares P., Fonseca , Wynford-Thomas D., Sobrinho-Simoes M. Sporadic ret-rearranged papillary carcinoma of the thyroid: a subset of slow growing, less aggressive thyroid neoplasms?. J. Pathol. 1998. Vol. 185. No. 1. P. 71-78.
  82. Tallini G., Santoro M., Helie M. et al. RET/PTC oncogene activation defines a subset of papillary thyroid carcinomas lacking evidence of progression to poorly differentiated or undifferentiated tumor phenotypes. Clin. Cancer Res. 1998. Vol. 4. No. 2. P. 287-294.
  83. Mochizuki K., Kondo T., Nakazawa T. et al. RET rearrangements and BRAF mutation in undifferentiated thyroid carcinomas having papillary carcinoma components. Histopathology. 2010. Vol. 57. No. 3. P. 444-450.
  84. Haymart R. Understanding the relationship between age and thyroid cancer. Oncologist. 2009. Vol. 14. No. 3. P. 216-221.
  85. Learoyd L., Messina M., Zedenius J. et al. RET/PTC and RET tyrosine kinase expression in adult papillary thyroid carcinomas. J. Clin. Endocrinol. Metab. 1998. Vol. 83. No. 10. P. 3631-3635.
  86. Elisei R., Romei C., Vorontsova T. et al. E. RET/PTC rearrangements in thyroid nodules: studies in irradiated and not irradiated, malignant and benign thyroid lesions in children and adults. J. Clin. Endocrinol. Metab. 2001. Vol. 86. No. 7. P. 3211-3216.
  87. Basolo F., Molinaro , Agate L. et al. RET protein expression has no prognostic impact on the long-term outcome of papillary thyroid carcinoma. Eur. J. Endocrinol. 2001. Vol. 145. No. 5. P. 599-604.
  88. Puxeddu E., Moretti S., Giannico A. et al. RET/PTC activation does not influence clinical and pathological features of adult papillary thyroid carcinomas. Eur. J. Endocrinol. 2003. Vol. 148. No. 5. P. 505-513.
  89. Brzezianska E., Karbownik M., Migdalska-Sek M. et al. Molecular analysis of the RET and NTRK1 gene rearrangements in papillary thyroid carcinoma in the Polish population. Mutat. Res. 2006. Vol. 599. No. 1-2. P. 26-35.
  90. Moses W., Weng , Khanafshar E. et al. Multiple genetic alterations in papillary thyroid cancer are associated with younger age at presentation. J. Surg. Res. 2010. Vol. 160. No. 2. P. 179-183.
  91. Rao P.J., Vardhini V., Parvathi M.V. et al. Prevalence of RET/PTC1 and RET/PTC3 gene rearrangements in Chennai population and its correlation with clinical parameters. Tumour Biol. 2014. Vol. 35. No. 10. P. 9539-9548.
  92. Bongarzone I., Fugazzola L., Vigneri P. et al. Age-related activation of the tyrosine kinase receptor protooncogenes ret and NTRK1 in papillary thyroid carcinoma. J. Clin. Endocrinol. Metab. 1996. Vol. 81. No. 5. P. 2006-2009.
  93. Nikiforov Y.E., Rowland M., Bove K.E. et al. Distinct pattern of ret oncogene rearrangements in morphological variants of radiation-induced and sporadic thyroid papillary carcinomas in children. Cancer Res. 1997. Vol. 57. No. 9. P. 1690-1694.
  94. Fenton L., Lukes Y., Nicholson D. et al. The RET/PTC mutations are common in sporadic papillary thyroid carcinoma of children and young adults. J. Clin. Endocrinol. Metab. 2000. Vol. 85. No. 3. P. 1170-1175.
  95. Wiench M., Wloch J., Oczko M. et al. Rearrangement of the RET gene in papillary thyroid carcinoma. Wiad. Lek. 2001. Vol. 54. Suppl 1. P. 64-71.
  96. Nakazawa T., Kondo T., Kobayashi Y. et RET gene rearrangements (RET/PTC1 and RET/PTC3) in papillary thyroid carcinomas from an iodine-rich country (Japan). Cancer. 2005. Vol. 104. No. 5. P. 943-951.
  97. Pellegriti G., Frasca F., Regalbuto C. et al. Worldwide increasing incidence of thyroid cancer: update on epidemiology and risk factors. J. Cancer Epidemiol. 2013. Article ID 965212, 10 p.
  98. Holm L., Dahlqvist I., Israelsson A., Lundell G. Malignant thyroid tumors after iodine-131 therapy: a retrospective cohort study. N. Engl. J. Med. 1980. Vol. 303. No. 4. P. 188-191.
  99. Hahn K., Schnell-Inderst P., Grosche B., Holm L.E. Thyroid cancer after diagnostic administration of iodine-131 in childhood. Radiat. Res. 2001. 156. No. 1. P. 61-70.
  100. Hall P., Mattsson , Boice J.D. Jr. Thyroid cancer after diagnostic administration of iodine-131. Radiat. Res. 1996. 145. No. 1. P. 86-92.
  101. Holm L.-E. Thyroid cancer after exposure to radioactive 131I. Acta Oncol. 2006. 45. No. 8. P. 1037-1040.
  102. UNSCEAR 2013. Report to the General Assembly, with Scientific Vol. II. Annex B. Effects of radiation exposure of children. New York. 2013. P. 1-268.
  103. Boice D., Jr. Thyroid disease 60 years after Hiroshima and 20 years after Chernobyl. JAMA. 2006. Vol. 295. No. 9. P. 1060-1062.
  104. Martin J., Sutton D.G., West C.M., Wright E.G. The radiobiology/radiation protection interface in healthcare. J. Radiol. Prot. 2009. 29. No. 2A. P. A1-A20.
  105. UNSCEAR Report to the General Assembly, with Scientific Annexes. Annex A. Attributing health effects to ionizing radiation exposure and inferring risks. United Nations. New York. 2015. 86 p.
  106. Jaworowski Z. Observations on the Chernobyl disaster and LNT. Dose 2010. Vol. 8. No. 2. P. 148- 171.
  107. Ilyn A. Chernobyl: Myth and Reality. Moscow. Megapolis English edition. 1995. 398 p.
  108. Yarmonenko S. P. Radiobiology of Humans and Animals. Moscow: Mir Publishers. 1988. (English).
  109. Yarmonenko S.P. Problems of radiobiology at the end of the 20th century. Radiat. Biology. Radioecology (Moscow). 1997. Vol. 37. No. 4. P. 488-493. (Russian with English summary. PubMed. This source: ‘Yarmonenko’).

For citation: Koterov AN, Ushenkova LN, Biryukov AP, Samoilov AS. RET/PTC Gene Rearrangements Frequency in Papillary Thyroid Carcinoma Worldwide Depending on Time after Chernobyl Nuclear Power Plant Accident (Pooled-Analysis). Possible Contribution of Factors of Diagnosis, 'Aggressive Surgery', Radiation, and Age. Medical Radiology and Radiation Safety. 2016;61(5):27-41.

PDF (ENG) Full-text article